Cancer Treatment Specialties
Systemic anticancer therapy based on the molecular profile of each tumor. Chemotherapy, targeted therapy, immunotherapy — an individualized approach grounded in international clinical evidence.
Areas of Expertise in Systemic Cancer Treatment
Each specialty requires its own approach to molecular diagnostics and individualized treatment selection. Dr. Ledin has extensive experience across all listed areas, with particular depth in gastrointestinal oncology.
Gastric cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma, esophageal cancer. Molecular profiling: MSI, RAS, BRAF, HER2, PD-L1.
Primary specialization Learn more →Subtype-specific treatment: luminal A/B, HER2-positive, triple-negative. Hormonal therapy, targeted therapy (trastuzumab, T-DXd), immunotherapy, PARP inhibitors.
Molecular subtype determines treatment Learn more →NSCLC and SCLC. Targeted therapy for EGFR, ALK, ROS1, BRAF, KRAS G12C, RET, MET, NTRK mutations. Immunotherapy based on PD-L1 expression.
8+ targetable mutations Learn more →BRAF/MEK targeted therapy, immunotherapy (anti-PD-1, anti-CTLA-4). Cutaneous, mucosal, and uveal melanoma. Participant in the ADMIRE clinical trial.
BRAF status determines strategy Learn more →Ovarian cancer, cervical cancer, endometrial cancer. BRCA/HRD testing, PARP inhibitors, immunotherapy. Molecular classification guides treatment.
BRCA/HRD — key to treatment Learn more →Kidney cancer (RCC), bladder cancer (urothelial carcinoma), prostate cancer. TKI + immunotherapy, novel antiandrogens, PARP inhibitors for HRD+ cases.
Targeted + immunotherapy Learn more →Precision Oncology: Treatment Guided by Science
Precision oncology means that treatment decisions are based not only on tumor location and stage, but on its molecular and biological characteristics. The same cancer type may harbor fundamentally different molecular drivers — and therefore require different therapeutic strategies.
Dr. Ledin determines the complete molecular profile of each tumor before initiating treatment. This ensures access to the full arsenal of modern therapies, including targeted agents and immunotherapy, rather than relying solely on standard chemotherapy.
Every tumor has its own biology. Molecular profiling reveals the specific vulnerabilities of each cancer — and opens the door to the most effective treatment available today.
Experience, Science, and Individualized Care
Over two decades of practice at the N.N. Blokhin National Medical Research Center of Oncology and the De Vita clinic. Thousands of patients treated across multiple cancer types.
Published in The Lancet, The Lancet Oncology, Journal of Clinical Oncology (JCO), and New England Journal of Medicine (NEJM). Co-author of RUSSCO national clinical guidelines.
Principal investigator in international Phase II and III clinical trials (IMbrave050, MATTERHORN, ADMIRE, and others). Access to cutting-edge treatment approaches.
RUSSCO — Russian Society of Clinical Oncology. ESMO — European Society for Medical Oncology. ASCO — American Society of Clinical Oncology.
Schedule a Consultation
Tell us about your situation — we will help determine the next steps
Or contact us directly: